Biomarin Pharmaceutical Inc (BMRN)
66.00
-0.60
(-0.90%)
USD |
NASDAQ |
Nov 04, 16:00
66.78
+0.78
(+1.18%)
After-Hours: 06:41
Biomarin Pharmaceutical Cash from Financing (Quarterly): -499.12M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -499.12M |
| June 30, 2024 | 12.61M |
| March 31, 2024 | -42.79M |
| December 31, 2023 | 10.84M |
| September 30, 2023 | -0.788M |
| June 30, 2023 | 11.96M |
| March 31, 2023 | -40.74M |
| December 31, 2022 | 10.87M |
| September 30, 2022 | 7.541M |
| June 30, 2022 | -11.78M |
| March 31, 2022 | -25.28M |
| December 31, 2021 | 14.40M |
| September 30, 2021 | -1.031M |
| June 30, 2021 | 10.95M |
| March 31, 2021 | -24.36M |
| December 31, 2020 | -366.16M |
| September 30, 2020 | 3.256M |
| June 30, 2020 | 563.69M |
| March 31, 2020 | -19.67M |
| December 31, 2019 | 4.042M |
| September 30, 2019 | -1.975M |
| June 30, 2019 | -51.76M |
| March 31, 2019 | -24.98M |
| December 31, 2018 | -366.36M |
| September 30, 2018 | 5.151M |
| Date | Value |
|---|---|
| June 30, 2018 | -17.03M |
| March 31, 2018 | -9.765M |
| December 31, 2017 | 13.10M |
| September 30, 2017 | 481.94M |
| June 30, 2017 | 18.86M |
| March 31, 2017 | -6.743M |
| December 31, 2016 | 19.91M |
| September 30, 2016 | 737.00M |
| June 30, 2016 | 7.454M |
| March 31, 2016 | -37.26M |
| December 31, 2015 | 9.518M |
| September 30, 2015 | 3.765M |
| June 30, 2015 | -2.351M |
| March 31, 2015 | 914.79M |
| December 31, 2014 | 41.52M |
| September 30, 2014 | 8.871M |
| June 30, 2014 | -3.159M |
| March 31, 2014 | 136.96M |
| December 31, 2013 | 704.93M |
| September 30, 2013 | 12.30M |
| June 30, 2013 | 15.62M |
| March 31, 2013 | 13.82M |
| December 31, 2012 | 39.56M |
| September 30, 2012 | 10.31M |
| June 30, 2012 | 248.97M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-499.12M
Minimum
Sep 2024
563.69M
Maximum
Jun 2020
-19.08M
Average
1.234M
Median
Cash from Financing (Quarterly) Benchmarks
| Merck & Co Inc | 1.216B |
| Bristol-Myers Squibb Co | -3.852B |
| Alnylam Pharmaceuticals Inc | 102.76M |
| Bioventus Inc | -7.845M |
| Moderna Inc | 34.00M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 221.48M |
| Cash from Investing (Quarterly) | -16.16M |
| Free Cash Flow | 300.88M |
| Free Cash Flow Per Share (Quarterly) | 1.016 |
| Free Cash Flow to Equity (Quarterly) | 694.63M |
| Free Cash Flow to Firm (Quarterly) | 200.30M |
| Free Cash Flow Yield | 2.32% |